Meta‐analysis of drug‐related deaths soon after release from prison
Dados Bibliográficos
| ID | 23385342 |
|---|---|
| Autores | Elizabeth L C Merrall, Elizabeth Merrall (MRC Biostatistics Unit, autor correspondente), Azar Kariminia (0000-0003-4513-3045, National Centre for Clinical Research on Emerging Drugs), Ingrid Binswanger (0000-0001-8862-8078, Denver Health Medical Center), Ingrid A Binswanger, Michael Hobbs (0000-0002-7556-6274, The University of Western Australia), Michael S Hobbs, Michael Farrell (0000-0002-0634-9719, King's College London), John Marsden (0000-0002-1307-2498, King's College London), Sharon Hutchinson (0000-0002-6891-6758, University of Strathclyde), Sharon J Hutchinson, Sheila M Bird (0000-0001-6378-8382, University of Strathclyde) |
| Ano | 2010 |
| Volume | 105 |
| Fascículo | 9 |
| Páginas | 1545-1554 |
| Data de publicação | 2010-09-01 |
| Peer Reviewed | Sim |
| Open Access | Sim |
| Tipo | ARTICLE |
| Periódico | Addiction (JOURNAL) |
| Identificadores do periódico | ISSN: 0965-2140 • E-ISSN: 1360-0443 |
| Editora | Wiley (PUBLISHER • GB) |
| DOI | 10.1111/j.1360-0443.2010.02990.x |
| PMID | 20579009 |
| PMCID | PMC2955973 |
| OpenAlex | W2118672557 |
| Idioma | EN |
| Citações recebidas | 135 |
| Referências citadas | 32 |
Aims The transition from prison back into the community is particularly hazardous for drug‐using offenders whose tolerance for heroin has been reduced by imprisonment. Studies have indicated an increased risk of drug‐related death soon after release from prison, particularly in the first 2 weeks. For precise, up‐to‐date understanding of these risks, a meta‐analysis was conducted on the risk of drug‐related death in weeks 1 + 2 and 3 + 4 compared with later 2‐week periods in the first 12 weeks after release from prison. Methods English‐language studies were identified that followed up adult prisoners for mortality from time of index release for at least 12 weeks. Six studies from six prison systems met the inclusion criteria and relevant data were extracted independently. Results These studies contributed a total of 69 093 person‐years and 1033 deaths in the first 12 weeks after release, of which 612 were drug‐related. A three‐ to eightfold increased risk of drug‐related death was found when comparing weeks 1 + 2 with weeks 3–12, with notable heterogeneity between countries: United Kingdom, 7.5 (95% CI: 5.7–9.9); Australia, 4.0 (95% CI: 3.4–4.8); Washington State, USA, 8.4 (95% CI: 5.0–14.2) and New Mexico State, USA, 3.1 (95% CI: 1.3–7.1). Comparing weeks 3 + 4 with weeks 5–12, the pooled relative risk was: 1.7 (95% CI: 1.3–2.2). Conclusions These findings confirm that there is an increased risk of drug‐related death during the first 2 weeks after release from prison and that the risk remains elevated up to at least the fourth week.
Criminology · Drug · Heroin · Imprisonment · Meta-analysis · Prison · Psychiatry · Criminal Justice and Corrections Analysis · Demography · Internal Medicine · Medicine · Opioid Use Disorder Treatment · Psychology · Substance Abuse Treatment and Outcomes
How to Talk with Patients about Incarceration and Health
Toxicology of Scotland's drugs-related deaths in 2000–2007
Examining Factors Associated with Non-Fatal Overdose among People Who Inject Drugs in Rural Appalachia
Structures of survival
“From the prison door right to the sidewalk, everything went downhill,” A qualitative study of the health experiences of recently released inmates
Mortality After Prison Release
Stigma as a fundamental hindrance to the United States opioid overdose crisis response
Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs
Global patterns of opioid use and dependence
A conceptual model for understanding post-release opioid-related overdose risk
Extent of illicit drug use and dependence, and their contribution to the global burden of disease
Responding to the opioid crisis in North America and beyond
Signal of increased opioid overdose during Covid-19 from emergency medical services data
The Relationship between Lifetime Opioid Use and Mental and Physical Health among Incarcerated Individuals
The Accessibility of Opioid Agonist Treatment and Its Forced Discontinuation in Swiss Prisons—Attitudes, Perceptions and Experiences of Defense Lawyers in Dealing With Detained Persons Using Opioids
“My first 48 hours out”
Buprenorphine Induction in a Rural Maryland Detention Center During Covid-19
Probation, Parole, and Harm Reduction
Reducing opioid related deaths for individuals who are at high risk of death from overdose
Examining predictors of substance use and treatment adequacy among formerly incarcerated individuals with a history of opioid and cocaine use
Surdoses au Québec et inégalités sociales de santé
Déploiement d’un algorithme de soins en réponse à la crise des opioïdes
Explaining post-prison rehabilitation through music from the Good Lives Model perspective
Exploring Problematic Substance Use during Reentry from Prison to the Community
Buprenorphine Treatment Intake and Critical Encounters following a Nonfatal Opioid Overdose
Overdose Experiences Among a Sample of Women in Jail with Opioid Use Disorder
Identifying Multilevel Community Supervision Challenges to Inform Diversion Approaches for People With Mental Illnesses
Prevalence of illicit drug use before imprisonment in Europe
Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open‐label, non‐randomised trial of long‐acting injectable buprenorphine treatment in Australian custodial settings
Gender and Overdose Risk Factors Among Clients Entering Residential Treatment for Opioid Use
Feasibility and acceptability of take‐home naloxone for people released from prison in New South Wales, Australia
Methamphetamine use, health and criminal justice system outcomes
Factors Associated With Adult Incarceration Among People With Opioid Use Disorder in New South Wales, Australia
Experiences of People Who Discontinue Long‐Acting Injectable Buprenorphine Treatment Recently Released From Prison in New South Wales, Australia
Multiple Disadvantage and Social Networks
Delivering Peer-Based Support in Prisons During the Covid Pandemic and Lockdown
Bridge Over Troubled Waters? Certified Recovery Specialist Support and Community Reentry
What Are Community Supervision Officers’ Knowledge and Views of Naloxone? An Exploratory Study
Prison Visitation and All-Cause Mortality During Reentry
The Last Straw
“If We Could Identify Those Roadblocks, The Program Could Run Way Better”
“They talked to me like I was dirt under their feet
Factors associated with drug use in prison – results from the Norwegian offender mental health and addiction (NorMA) study
Rapid jail-based implementation of overdose education and naloxone distribution in response to the Covid-19 pandemic
Understanding the impact of Covid-19 on the delivery and receipt of prison healthcare
Deaths among adults under supervision of the England and Wales’ probation services
Reducing overdose after release from incarceration (Roar)
Overdose education and naloxone distribution in jails
Emergency room use after being released from incarceration
Community buprenorphine continuation post-release following extended release vs. sublingual buprenorphine during incarceration
Implementation of carceral medicaid suspension and enrollment programs
Medication assisted treatment (MAT) in criminal justice settings as a double-edged sword
Health-related factors predict return to custody in a large cohort of ex-prisoners
A participant-randomized pilot hybrid II trial of group cognitive processing therapy for incarcerated persons with posttraumatic stress and substance use disorder symptoms
Complex health-related needs among young, soon-to-be-released prisoners
Availability of best practices for opioid use disorder in jails and related training and resource needs
Medications for opioid use disorder during incarceration and post-release outcomes
Receptivity to Jail-based medication for opioid use disorder among rural detention Administrators
Health and Justice
Non-custodial deaths
Mass Imprisonment and Inequality in Health and Family Life
Prison Health Discharge Planning – Evidence of an Integrated Care Pathway or the End of the Road
Covid-19 Outbreaks at Correctional Facilities Demand a Health Equity Approach to Criminal Justice Reform
Examining Fatal Opioid Overdoses in Marion County, Indiana
Perceptions of Health-Related Community Reentry Challenges among Incarcerated Drug Users in Azerbaijan, Kyrgyzstan, and Ukraine
Take-Home Emergency Naloxone to Prevent Heroin Overdose Deaths after Prison Release
The Opioid Crisis
Mortality after release from incarceration in New Zealand by gender
PTSD diagnosis and nonmedical use of benzodiazepines among African American incarcerated men
A quantitative exploration of risk factors associated with drug-related deaths involving heroin, alcohol or methadone in the West of Scotland
Injecting drug users in Scotland, 2006
A record linkage study of hospital episodes for drug treatment clients in Scotland, 1996–2006
Attitudes Toward Addiction, Methadone Treatment, and Recovery Among HIV-Infected Ukrainian Prisoners Who Inject Drugs
Bereavement Following Substance Misuse
Until I get off parole … then I can swim in it if I want to
Prison Lethality
Gender and risk behaviors for HIV and sexually transmitted infections among recently released inmates
Prison health data collection
The impact of incarceration on health
The impact of trauma, substance abuse, and psychiatric illness on suicidal and self-harm behaviours in a cohort of migrant detainees
Rethinking Mandated Drug Treatment
Continuity of care for drug users in prison and beyond
An application of agent-based modeling to explore the impact of decreasing incarceration rates and increasing drug treatment access on sero-discordant partnerships among people who inject drugs
Understanding overdose incidents in Canadian federal custody
Framework for opioid use disorder screening and diagnosis in carceral settings
One guy goes to jail, two people are ready to take his spot”
Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone
Decisional considerations for methadone uptake in Kyrgyz prisons
Exploring the life-saving potential of naloxone
Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky
Perceived availability and carriage of take-home naloxone and factors associated with carriage among people who inject drugs in England, Wales and Northern Ireland
Quantity fluctuations of illicitly used opioids and overdose risk
Increasing drug-related mortality rates over the last decade in Scotland are not just due to an ageing cohort
Higher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia
Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison
Assessing HIV and overdose risks for people who use drugs exposed to compulsory drug abstinence programs (CDAP)
A mapping review of take-home naloxone for people released from correctional settings
Covid-19 vaccination uptake and risk of severe Covid-19 disease among those in, and released from, prison care in Scotland
Covid-19 and the health of people who use drugs
Continuity of opioid substitution treatment between prison and community in Southeast Asia
| Obras citantes distintas | 135 |
|---|---|
| Citações por ano | 9 |
| Intervalo de citações | 2011 - 2026 (16) |
| Velocidade de citação | current |
| Altamente citado | Sim |
| Tipos de citação | Neutras: 131 |